Changes in urinary arsenic methylation profiles in a 15-year interval after cessation of arsenic ingestion in Southwest Taiwan

Environmental Health Perspectives

Volumn 117, Issue 12, 2009, Pages 1860-1866

  Huang, Yung Kai ^a,g   Huang, Ya Li ^b   Hsueh, Yu Mei ^b,c   Wang, Jimmy Tse Jen ^d   Yang, Mo Hsiung ^e   Chen, Chien Jen ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^f GENOMICS RESEARCH CENTER   (Taiwan)

^g NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Arsenic methylation; Cumulative arsenic exposure; Drinking water

Indexed keywords

ARSENIC; CACODYLIC ACID; METHANEARSONIC ACID;

ADULT; AGED; ARSENIC POISONING; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INGESTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; METABOLISM; METHYLATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TAIWAN; URINE LEVEL;

ADULT; AGED; ARSENIC; ARSENICALS; CACODYLIC ACID; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TAIWAN; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

EID: 75349103065     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0900560     Document Type: Article

References (65)

1. Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, Jasmine F, et al. 2007. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol Biomarkers Prev 16:1270-1278.
2. ATSDR. 2000. Toxicological Profile for Arsenic. Atlanta, GA:Agency for Toxic Substances and Disease Registry. Available: http://www.atsdr.cdc.gov/ toxprofiles/tp2. html#bookmark06 [accessed 7 October 2009].
3. Buchet JP, Lauwerys R. 1987. Study of factors influencing the in vivo methylation of inorganic arsenic in rats. Toxicol Appl Pharmacol 91:65-74.
4. Buchet JP, Lauwerys R, Mahieu P, Geubel A. 1982. Inorganic arsenic metabolism in man. Arch Toxicol Suppl 5:326-327.
5. Buchet JP, Lauwerys R, Roels H. 1981. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111-118.
6. Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ. 1999. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 107:663-667.
7. Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892.
8. Chen CJ, Chuang YC, Lin TM, Wu HY. 1985. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895-5899.
9. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60.
10. Chen Y, Factor-Litvak P, Howe GR, Graziano JH, Brandt-Rauf P, Parvez F, et al. 2007. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. Am J Epidemiol 165:541-552.
11. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, et al. 2003a. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241-248.
12. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, et al. 2003b. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303-310.
13. Chowdhury UK, Rahman MM, Sengupta MK, Lodh D, Chanda CR, Roy S, et al. 2003. Pattern of excretion of arsenic compounds [arsenite, arsenate, MMA(V), DMA(V)] in urine of children compared to adults from an arsenic exposed area in Bangladesh. J Environ Sci Health Part A Toxic/Hazard Subst Environ Eng 38:87-113.
14. Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, et al. 2002. Family correlations of arsenic methyla tion patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 110:729-733.
15. Concha G, Nermell B, Vahter MV. 1998. Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ Health Perspect 106:355-359.
16. Concha G, Vogler G, Nermell B, Vahter M. 2002. Intra-individual variation in the metabolism of inorganic arsenic. Int Arch Occup Environ Health 75:576-580.
17. Coppin JF, Qu W, Waalkes MP. 2008. Interplay between cellular methyl metabolism and adaptive efflux during oncogenic transformation from chronic arsenic exposure in human cells. J Biol Chem 283:19342-19350.
18. Dewar WA, Lenihan JM. 1956. A case of chronic arsenical poisoning; examination of tissue samples by activation analysis. Scott Med J 1:236-238.
19. Fujihara J, Fujii Y, Agusa T, Kunito T, Yasuda T, Moritani T, et al. 2009. Ethnic differences in five intronic polymorphisms associated with arsenic metabolism within human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Toxicol Appl Pharmacol 234:41-46.
20. Fujihara J, Soejima M, Koda Y, Kunito T, Takeshita H. 2008. Asian specific low mutation frequencies of the M287T polymorphism in the human arsenic (+3 oxidation state) methyltransferase (AS3MT) gene. Mutat Res 654:158-161.
21. Gamble MV, Liu X, Ahsan H, Pilsner R, Ilievski V, Slavkovich V, et al. 2005. Folate, homocysteine, and arsenic metabolism in arsenic-exposed individuals in Bangladesh. Environ Health Perspect 113:1683-1688.
22. Gonsebatt ME, Vega L, Salazar AM, Montero R, Guzman P, Blas J, et al. 1997. Cytogenetic effects in human exposure to arsenic. Mutat Res 386:219-228.
23. Hernández A, Xamena N, Sekaran C, Tokunaga H, Sampayo-Reyes A, Quinteros D, et al. 2008. High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet Genomics 18:349-355.
24. Hindmarsh JT. 2002. Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem 35:1-11.
25. Hopenhayn-Rich C, Biggs ML, Kalman DA, Moore LE, Smith AH. 1996a. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ Health Perspect 104:1200-1207.
26. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. 1996b. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620-628.
27. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, et al. 1997. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589-596.
28. Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ. 2002. Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83-91.
29. Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, et al. 1998. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 54:431-444.
30. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL, et al. 2003. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 137:49-63.
31. Huang YK, Huang YL, Hsueh YM, Yang MH, Wu MM, Chen SY, et al. 2008. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 19(8):829-839.
32. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. 2007. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol Appl Pharmacol 218:135-142.
33. Hughes MF, Kenyon EM, Edwards BC, Mitchell CT, Razo LM, Thomas DJ. 2003. Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol Appl Pharmacol 191:202-210.
34. IARC (International Agency for Research on Cancer). 1980. Some Metals and Metallic Compounds. IARC Monogr Eval Carcinog Risk Hum 23:1-438.
35. Kenyon EM, Hughes MF, Adair BM, Highfill JH, Crecelius EA, Clewell HJ, et al. 2008. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water. Toxicol Appl Pharmacol 232:448-455; doi:10.1016/j.taap.2008.07.018 [Online 28 July 2008].
36. Kuo TL. 1964. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7-13.
37. Kurttio P, Komulainen H, Hakala E, Kahelin H, Pekkanen J. 1998. Urinary excretion of arsenic species after exposure to arsenic present in drinking water. Arch Environ Contam Toxicol 34:297-305.
38. Le XC, Cullen WR, Reimer KJ. 1994. Human urinary arsenic excretion after one-time ingestion of seaweed, crab, and shrimp. Clin Chem 40:617-624.
39. Mandal BK, Ogra Y, Suzuki KT. 2001. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol 14:371-378.
40. Marafante E, Bertolero F, Edel J, Pietra R, Sabbioni E. 1982. Intracellular interaction and biotransformation of arsenite in rats and rabbits. Sci Total Environ 24:27-39.
41. Marnell LL, Garcia-Vargas GG, Chowdhury UK, Zakharyan RA, Walsh B, Avram MD, et al. 2003. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507-1513.
42. Meza MM, Kopplin MJ, Burgess JL, Gandolfi AJ. 2004. Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico. Environ Res 96:119-126.
43. Mühlberg W, Platt D. 1999. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45:243-253.
44. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, et al. 2002. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 110:331-336.
45. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW-H, et al. 2007. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99-106.
46. Schläwicke Engström K, Broberg K, Concha G, Nermell B, Warholm M, Vahter M. 2007. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ Health Perspect 115:599-605.
47. Schläwicke Engström K, Nermell B, Concha G, Stromberg U, Vahter M, Broberg K. 2009. Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat Res 667(1-2):4-14.doi:10.1016/j.mrfmmm.2008.07.003 [Online 10 July 2009].
48. Schmuck EM, Board PG, Whitbread AK, Tetlow N, Cavanaugh JA, Blackburn AC, et al. 2005. Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Pharmacogenet Genomics 15:493-501.
49. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA, et al. 2006. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med 48:478-488.
50. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. 2005. Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919-924.
51. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, et al. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289-299.
52. Thomas DJ, Styblo M, Lin S. 2001. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127-144.
53. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, Chen CJ, et al. 2005. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol Appl Pharmacol 206:299-308.
54. Vahter M. 1999. Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82:69-88.
55. Vahter M. 2000. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112-113:209-217.
56. Vahter ME. 2007. Interactions between arsenic-induced toxicity and nutrition in early life. J Nutr 137:2798-2804.
57. Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT. 1995. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455-462.
58. Vahter M, Norin H. 1980. Metabolism of 74As-labeled trivalent and pentavalent inorganic arsenic in mice. Environ Res 21:446-457.
59. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, Calderon-Aranda ES, et al. 2005. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250-254.
60. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. 2001. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225-232.
61. Wood TC, Salavaggione OE, Mukherjee B, Wang L, Klumpp AF, Thomae BA, et al. 2006. Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364-7373.
62. Wu HY, Chen KP, Tseng WP, Hsu CL. 1961. Epidemiologic studies on blackfoot disease: I. Prevalence and incidence of the disease by age, sex, occupation and geographical distribution. Mem College Med Natl Taiwan Univ 7:33-50.
63. Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130:1123-1132.
64. Yamauchi H, Yamamura Y. 1985. Metabolism and excretion of orally administrated arsenic trioxide in the hamster. Toxicology 34:113-121.
65. Yu RC, Hsu KH, Chen CJ, Froines JR. 2000. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259-1262.